Liposarcoma
📧 Sign up to get email alerts when something new happens for Liposarcoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-06-09FDA Approved: ERIBULIN MESYLATE — Original Application (Sandoz Inc)
The FDA approved Sandoz's original ANDA for ERIBULIN MESYLATE, authorizing the generic product's marketing in the United States.
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor [Phase 1, Phase 2]
Multicohort Phase 1/2 clinical trial evaluating PM14 as monotherapy and in combination with radiotherapy for soft tissue sarcoma and other s…
-
FDA approval · 2025-03-04FDA Approved: ERIBULIN MESYLATE — Original Application (Sun Pharmaceutical Industries Limited)
FDA approved Sun Pharmaceutical Industries Limited's original ANDA for eribulin mesylate, confirming a generic version of the cancer drug. T…
-
CLINICAL_TRIALS research · 2025-02-26Clinical Trial Update: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update describing an ongoing Phase 1/2 study of APG-115 in combination with a PD-1 inhibitor for patients with liposarcoma or…
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas [NA]
A clinical trial update describes the identification of a new blood biomarker for diagnosing liposarcoma and atypical lipomatous tumor and f…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-11-25Clinical Trial Update: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma [Phase 1, Phase 2]
Phase 1/2 study evaluating lenvatinib and eribulin in advanced soft tissue sarcoma has completed with posted results. The study includes lei…
-
EMA approval · 2024-10-16EMA Authorised: Mevlyq (Eribulin mesylate) — YES Pharmaceutical Development Services GmbH
The EMA authorised Mevlyq (eribulin mesylate) for breast cancer and liposarcoma, with marketing authorisation holder YES Pharmaceutical Deve…
-
EMA approval · 2024-10-11EMA Authorised: Halaven (Eribulin) — Eisai GmbH
The EMA authorised Halaven (eribulin) for breast neoplasms and liposarcoma under Eisai GmbH, with a decision date of 26 July 2024.
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas [Phase 2]
Phase 2 clinical trial of sitravatinib in advanced liposarcoma and other soft tissue sarcomas has completed and results have been posted. Th…
-
FDA approval · 2024-07-18FDA Approved: ERIBULIN MESYLATE — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' original ANDA for eribulin mesylate, authorizing the generic manufacturing of this cancer drug.
-
FDA approval · 2024-04-05FDA Approved: ERIBULIN MESYLATE — Original Application (Gland Pharma Limited)
FDA approved an original (generic) application for Eribulin Mesylate from Gland Pharma Limited, authorizing the generic version of the produ…
-
CLINICAL_TRIALS trial_result · 2023-12-06Clinical Trial Update: ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma [Phase 2]
Phase 2 clinical trial update for ATX-101 in advanced dedifferentiated liposarcoma and leiomyosarcoma has been terminated with results poste…
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma [Phase 2]
Phase 2 trial evaluating doxorubicin with upfront dexrazoxane for advanced or metastatic soft tissue sarcoma has completed enrollment with r…
-
CLINICAL_TRIALS trial_result · 2023-11-07Clinical Trial Update: SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes [Phase 2]
Phase 2 trial evaluating oral regorafenib across selected sarcoma subtypes has completed enrollment with results posted.
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents [Phase 1, Phase 2]
Phase 1/2 trial evaluating OR2805, a anti-CD163 monoclonal antibody, alone and with anticancer agents for solid tumors, with unspecified sta…
-
CLINICAL_TRIALS trial_result · 2022-04-29Clinical Trial Update: Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery [Phase 1, Phase 2]
Clinical trial evaluating avelumab plus trabectedin in metastatic or unresectable liposarcoma and leiomyosarcoma; the study has terminated w…
-
CLINICAL_TRIALS trial_result · 2021-11-01Clinical Trial Update: Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma [Phase 2]
Phase 2 trial update on trabectedin for liposarcoma and leiomyosarcoma completed.
-
CLINICAL_TRIALS trial_result · 2021-03-16Clinical Trial Update: Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma [NA]
This completed clinical trial evaluated 54 Gy helical Tomotherapy radiotherapy followed by surgery for liposarcoma, with results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-10Clinical Trial Update: Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas [Phase 2]
Phase 2 trial evaluating pazopanib hydrochloride combined with topotecan hydrochloride in adults with metastatic or recurrent soft tissue an…
-
EMA label_change · 2020-07-24Authorised uses of cancer medicine Yondelis unchanged following review of new data
The EMA review concluded that the authorised uses of Yondelis (trabectedin) remain unchanged after evaluating new data.
-
CLINICAL_TRIALS trial_result · 2020-07-23Clinical Trial Update: Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial [Phase 2]
Phase II trial evaluating pazopanib for advanced or metastatic liposarcoma with results posted after completion.
-
CLINICAL_TRIALS trial_result · 2020-06-16Clinical Trial Update: Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery [Phase 2]
A Phase 2 trial evaluating nivolumab with or without ipilimumab in metastatic or unresectable sarcoma shows results from a completed study.
-
CLINICAL_TRIALS trial_result · 2020-05-14Clinical Trial Update: Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) [Phase 2]
Phase 2 trial evaluating CMB305 with atezolizumab versus atezolizumab alone in various sarcomas has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2019-06-27Clinical Trial Update: Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery [Phase 2]
Phase 2 study of efatutazone dihydrochloride in patients with previously treated myxoid liposarcoma that cannot be removed surgically has co…
-
CLINICAL_TRIALS withdrawal · 2019-05-13Clinical Trial Update: Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin [Phase 3]
A Phase 3 trial studying trabectedin for leiomyosarcoma, liposarcoma, and synovial sarcoma was withdrawn.